ANCA-associated Vasculitis Overview
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. This inflammation is typically caused by ANCAs, self-reactive antibodies that bind to certain cells of the immune system &mdash; called neutrophils &mdash; and overly activate them.
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/anca-associated-vasculitis-epidemiology-forecast" target="_blank" rel="noopener noreferrer">ANCA-associated Vasculitis Market</a> Insight (2022)
The ANCA-associated Vasculitis Market size in the 7MM was valued ~USD 1.4 billion in the year 2022
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/anca-associated-vasculitis-epidemiology-forecasts" target="_blank" rel="noopener noreferrer">ANCA-associated Vasculitis Epidemiology</a> Insights (2022)
<ul>
<li>The overall Diagnosed prevalent cases of ANCA-associated Vasculitis are-</li>
<li>The total diagnosed prevalent cases of ANCA-associated Vasculitis in the 7MM was ~208K cases</li>
<li>The total diagnosed prevalent cases of ANCA-associated Vasculitis in the United States was ~34% cases</li>
<li>The total diagnosed prevalent cases of ANCA-associated Vasculitis in the EU4 and the UK was ~42% cases</li>
<li>The total diagnosed prevalent cases of ANCA-associated Vasculitis in the Japan was ~24% cases</li>
</ul>
&nbsp;
ANCA-associated Vasculitis Epidemiology Segmentation in the 7MM from 2019 to 2032
<ul>
<li>Prevalent Cases</li>
<li>Type-specific Diagnosed Cases</li>
<li>Treatable Cases</li>
</ul>
&nbsp;
ANCA-associated Vasculitis Emerging Drugs
<ul>
<li>Depemokimab (GSK3511294): GlaxoSmithKline</li>
<li>FASENRA (benralizumab): AstraZeneca</li>
<li>Vilobelimab (IFX-1): InflaRx, and others</li>
</ul>

ANCA Associated Vasculitis Market

ANCA Associated Vasculitis Market Infographics 

ANCA Associated Vasculitis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape